407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

by Adil Daud, Rom Leidner, Ezra Cohen, Matthew Reilley, Siwen Hu-Lieskovan, Raphael Clynes, Roger Cohen, John Thompson, Mark Stein, Alain Mita, Bartosz Chmielowski, Yana Najjar, Elaine Shum, R Donald Harvey, Catherine Fleener, Ying Ding, Sowmya Chollate, Hector Avina, Jolene Shorr, Barbara Hickingbottom
Published 2020-11-01